Forte Biosciences (FBRX) Cash from Investing Activities (2016 - 2025)
Forte Biosciences' (FBRX) quarterly Cash from Investing Activities came in at -$55000.0 in Q3 2025, down 100.15% on a QoQ basis from $36.3 million in Q1 2025.
Forte Biosciences (FBRX) Cash from Investing Activities (2016 - 2025) Analysis & Trends
Forte Biosciences (FBRX) has 8 years of Cash from Investing Activities data on file, last reported at -$55000.0 in Q3 2025.
- On a quarterly basis, Cash from Investing Activities changed N/A year-over-year to -$55000.0 in Q3 2025; TTM through Mar 2026 was -$55000.0, a 118.21% decrease from a year earlier, with the FY2025 full-year figure at $36.2 million, up 200.67% from the prior year.
- Cash from Investing Activities for Q3 2025 stood at -$55000.0, down from $36.3 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for FBRX reached as high as $36.3 million in Q1 2025 and fell as low as -$36.0 million in Q4 2024.
- Historically, Cash from Investing Activities has averaged $1.7 million across 3 years, with a median of -$11000.0 in 2023.
- Across the five-year window, Cash from Investing Activities tumbled 224818.75% in 2024 and jumped 604916.67% in 2025, its largest moves.
- Year by year, Cash from Investing Activities stood at -$16000.0 in 2023, then tumbled by 224818.75% to -$36.0 million in 2024, then soared by 99.85% to -$55000.0 in 2025.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$55000.0 in Q3 2025, $36.3 million in Q1 2025, and -$36.0 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.75 Bn | 467.96 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.14 Bn | 114.89 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Forte Biosciences | 1.36 Bn | 1.31 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -55,000.00 |
| Sep 30, 2025 | -55,000.00 |
| Mar 31, 2025 | 36.29 Mn |
| Mar 31, 2025 | 36.29 Mn |
| Dec 31, 2024 | -35.99 Mn |
| Dec 31, 2024 | -35.99 Mn |
| Mar 31, 2024 | -6,000.00 |
| Mar 31, 2024 | -6,000.00 |
| Dec 31, 2023 | -16,000.00 |
| Dec 31, 2023 | -16,000.00 |
| Sep 30, 2023 | 10.03 Mn |
| Sep 30, 2023 | 10.03 Mn |
| Sep 30, 2020 | -1,000.00 |
| Sep 30, 2020 | -1,000.00 |
| Jun 30, 2020 | -9.14 Mn |
| Jun 30, 2020 | -9.14 Mn |
| Mar 31, 2020 | 12.72 Mn |
| Mar 31, 2020 | 12.72 Mn |
| Dec 31, 2019 | -89,000.00 |
| Dec 31, 2019 | -89,000.00 |